Intravenous Zanamivir: A Viable Option for Critically Ill Patients With Influenza.
CONCLUSIONS: The available information suggests that the intravenous formulation of zanamivir offers a viable alternative treatment for critically ill patients with influenza, especially when resistance to other agents is present. PMID: 33016090 [PubMed - as supplied by publisher]
long Xu Janus kinase (JAK) inhibitors have been developed as novel immunomodulatory drugs and primarily used for treating rheumatoid arthritis and other inflammatory diseases. Recent studies have suggested that this category of anti-inflammatory drugs could be potentially useful for the control of inflammation “storms” in respiratory virus infections. In addition to their role in regulating immune cell functions, JAK1 and JAK2 have been recently identified as crucial cellular factors involved in influenza A virus (IAV) replication and could be potentially targeted for antiviral therapy. Gingerenone ...
CONCLUSION: After outpatient episode incidence of influenza, antiviral treatment has been shown to reduce the incidence of hospitalized pneumonia, especially in infants and children, during pandemic season 2017. Antiviral therapy for influenza is recommended to minimize burden caused by influenza virus infection and to reduce pneumonia. In addition, medical costs of hospitalization may decrease by antiviral therapy, especially in infants and children. PMID: 32989929 [PubMed - in process]
Publication date: Available online 25 September 2020Source: Antiviral ResearchAuthor(s): Reiko Saito, Hidekazu Osada, Keita Wagatsuma, Irina Chon, Isamu Sato, Takashi Kawashima, Tadashi Saito, Naoki Kodo, Yasuhiko Ono, Yasushi Shimada, WintWint Phyu, Yugo Shobugawa
This study is the first to provide a direct link between this inflammation and plaque development - by way of IFITM3. Scientists know that the production of IFITM3 starts in response to activation of the immune system by invading viruses and bacteria. These observations, combined with the new findings that IFITM3 directly contributes to plaque formation, suggest that viral and bacterial infections could increase the risk of Alzheimer's disease development. Indeed, researchers found that the level of IFITM3 in human brain samples correlated with levels of certain viral infections as well as with gamma-secretase activ...
CONCLUSION: The clarithromycin-naproxen-oseltamivir combination group experienced a more rapid defervescence and a more rapid decline of influenza virus titer than the group treated with oseltamivir alone. Further consideration should be given to whether the overall benefits of combination therapy in hospitalized pediatric influenza patients outweigh the risks. PMID: 32978076 [PubMed - as supplied by publisher]
Publication date: Available online 14 August 2020Source: Antiviral ResearchAuthor(s): Mira C. Patel, Vasiliy P. Mishin, Juan A. De La Cruz, Anton Chesnokov, Ha T. Nguyen, Malania M. Wilson, John Barnes, Rebecca J.G. Kondor, David E. Wentworth, Larisa V. Gubareva
Publication date: Available online 1 August 2020Source: Antiviral ResearchAuthor(s): Dagmara Bialy, Holly Shelton
Publication date: Available online 1 August 2020Source: Antiviral ResearchAuthor(s): Peter G. Mohr, Janelle Williams, Masato Tashiro, Victor A. Streltsov, Jennifer L. McKimm-Breschkin
Abstract Outbreak of Coronavirus disease 2019 (COVID-19) started in mid of December 2019 and spread very rapidly across the globe within a month of its outbreak. Researchers all across the globe started working to find out its possible treatments. However, most of initiatives taken were based on various hypotheses and till date no successful treatments have been achieved. Some strategies adopted by China where existing antiviral therapy was initially used to treat COVID-19 have not given very successful results. Researchers from Thailand explored the use of combination of anti-influenza drugs such as Oseltamivir, ...
Publication date: Available online 20 July 2020Source: Antiviral ResearchAuthor(s): Wentao Cai, Haimei Wen, Qinyang Zhou, Lei Wu, Yong Chen, Hongbo Zhou, Meilin Jin